Table 4.

Treatment-emergent all-causality adverse events occurring in ≥2 subjects in any treatment group (studies 1 and 2)

Study 1
	Lersivirine (250 mg once daily) + ketoconazole (400 mg once daily) (n = 14)	Lersivirine (250 mg once daily) + placebo (n = 14)
MedDRA preferred term, n (%)
Abdominal pain	2 (14)	0
Diarrhoea	5 (36)	2 (14)
Dyspepsia	3 (21)	0
Nausea	5 (36)	0
Headache	5 (36)	1 (7)
Pharyngolaryngeal pain	2 (14)	3 (21)

Study 2
	Lersivirine (500 mg once daily) + valproic acid (1000 mg once daily) (n = 14)	Lersivirine (500 mg once daily) + placebo (n = 14)
MedDRA preferred term, n (%)
Nausea	1 (7)	2 (14)
Vessel puncture site haematoma	2 (14)	0
Upper respiratory tract infection	0	2 (14)
Headache	2 (14)	0

MedDRA, medical dictionary for regulatory activities.